#1 Clinical Trials Search in Europe

Comparing cognitive behavioral therapy alone versus cognitive behavioral therapy combined with degarelix to prevent sexual offenses in patients with paraphilic disorders

1 1

What is this study about?

This study aims to assess the effectiveness of combining Cognitive Behavioral Therapy, a type of talk therapy that helps people change unhelpful thoughts and behaviors, with medication to reduce the risk of sexual offenses in individuals with Paraphilic disorder or Compulsive sexual behavior disorder. Participants may receive degarelix, a medication used to suppress hormone levels, alongside the therapy. In some cases, testosterone cipionate, a form of testosterone, may be provided through a gel applied to the skin to manage certain effects of the suppression medication.

The study compares different treatment approaches. Some participants will receive only the talk therapy, while others will receive the therapy combined with degarelix or a placebo. This research looks at how these different combinations affect behaviors and symptoms over time. Participants will be monitored for a period of time to observe changes in their behavior and physical health.

Who Can Join the Study?

  • Participants must be men between the ages of 18 and 70 years.
  • Participants must have a paraphilic disorder, which is a condition involving intense and persistent sexual interests that are unusual or may cause distress, or compulsive sexual behavior disorder, which involves difficulty controlling sexual urges.
  • Participants must show an increased risk of committing a sexual offense through one of these ways: having a previous conviction (a legal judgment that someone is guilty of a crime), having a high score on risk rating scales (specialized tools used by professionals to measure how likely someone is to repeat an offense), or being judged as high risk by the study researcher.
  • Participants must provide written consent, which means they must sign a document showing they agree to take part in the study.

Who Cannot Join the Study?

  • You have a known or suspected allergy, which is an immune system reaction, to any of the study medications.
  • You have significant kidney impairment, meaning your kidneys are not working properly, or your estimated glomerular filtration rate (a measure of how well your kidneys filter blood) is too low.
  • You have severe asthma, defined as having had multiple flare-ups requiring steroid treatment or hospital visits in the last year.
  • You have major cardiovascular risk factors, which are conditions that increase the chance of heart disease or stroke, such as atherosclerotic disease (hardened or blocked arteries), uncontrolled hypertension (high blood pressure), type 1 or type 2 diabetes, or familial hypercholesterolemia (a genetic condition causing high cholesterol).
  • You have a family history of premature myocardial or cerebral infarction, which means a parent had a heart attack or stroke before age 50.
  • You have an ongoing substance use disorder, which is a medical condition involving the harmful use of drugs or alcohol, including the recent use of illegal drugs.
  • You have previously participated in this specific study.
  • You have mental inability, reluctance, or language difficulties that make it hard to understand the study, follow instructions, or communicate in Swedish or English.
  • You are currently receiving treatments that affect the hypothalamic-pituitary-gonadal axis (the system of glands that controls hormones) or testicular function.
  • You have any other health conditions that, in the doctor’s opinion, could make participation unsafe or affect the study results.
  • The investigator (the main doctor in charge of the study) decides you are not suitable for the trial.
  • You have a known or suspected history of breast or prostate cancer.
  • You have conditions that require special warnings when using the study medications.
  • You have osteoporosis (weak or brittle bones) or a high calculated risk of breaking a bone in the next 10 years based on a tool called FRAX.
  • You have QT-c prolongation, which is a specific change in the electrical activity of your heart rhythm that lasts longer than normal.
  • You have major or uncontrolled liver disease or kidney disease that puts your health at risk.
  • You have significant hepatic impairment, meaning your liver is not functioning correctly, or your ALT or AST levels (enzymes measured in blood tests that indicate liver health) are much higher than normal.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Region Stockholm – SLSO Stockholm Sweden
Skaraborg Hospital-Vaestra Goetalandsregionen Skovde Sweden

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Sweden Sweden
Not yet recruiting
01.06.2026

Trial locations

Investigated drugs:

Testosterone is a hormone used in this study to study its effects on sexual behaviors. It is applied through the skin.

Degarelix is a medication used to lower the levels of testosterone in the body. It is given as an injection under the skin.

Investigated diseases:

Compulsive sexual behavior disorder – This condition involves a persistent pattern of failure to control intense, repetitive sexual impulses or urges. These urges may lead to sexual activities that cause significant distress or interfere with a person’s daily responsibilities and relationships. The behavior often becomes increasingly difficult to resist over time. It can involve an obsession with sexual thoughts or an inability to limit sexual activities. The condition typically progresses as the individual relies on these behaviors to cope with various emotions or stressors.

Trial ID:
2024-518120-68-01
Protocol code:
PREVENT-MED
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study on the Effects of Escitalopram, Naltrexone, and Their Combination on Reducing Symptoms of Compulsive Sexual Behavior Disorder in Affected Patients

    Recruiting

    1 1 1
    Investigated drugs:
    Poland

  • Study on the Effects of Escitalopram, Paroxetine, and Naltrexone for Patients with Compulsive Sexual Behavior Disorder

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Poland